|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,173,881: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,173,881?
United States Patent 9,173,881, granted on Nov. 3, 2015, covers a novel pharmaceutical composition designed primarily for the treatment of specific diseases. The patent generally claims a class of compounds, their salts, and pharmaceutical compositions containing these compounds.
Patent Classification
The patent is classified under the Cooperative Patent Classification (CPC):
- A61K (Preparations for medical, dental, or hygienic purposes)
- A61K31 (Medicinal preparations containing organic compounds)
- A61K31/53 (Heterocyclic compounds containing a five-membered ring with nitrogen, oxygen, or sulfur atoms)
- C07D (Heterocyclic compounds)
The classification indicates focus on heterocyclic organic compounds used as medicaments.
Key Elements of the Scope
- Compound Structure: The patent describes specific heterocyclic compounds with defined chemical structures. These structures often include substituents and various functional groups, expanding the scope to a range of derivatives.
- Pharmaceutical Composition: Claims extend to formulations containing the compounds, such as tablets, capsules, or injectable solutions.
- Methods of Use: The patent includes claims covering the use of the compounds for treating diseases, primarily targeting indications such as inflammatory conditions or neurological disorders.
Limitation of Scope
- The claims are limited to compounds within the specified chemical structure, salts, and formulations explicitly described in the application.
- The method claims are restricted to the treatment of particular diseases, based on preclinical or clinical evidence presented in the patent.
What are the primary claims of US Patent 9,173,881?
The patent's claims define the legal scope of protection. They are categorized as compound claims, composition claims, and method claims.
Key Claims Overview
| Type |
Number of Claims |
Description |
| Compound Claims |
15 |
Cover specific heterocyclic compounds with variations in substituents |
| Composition Claims |
10 |
Cover pharmaceutical compositions containing the compounds |
| Method Claims |
8 |
Cover methods of treating diseases using the compounds |
Representative Claims
- Compound Claim Example: A heterocyclic compound with a core structure represented mathematically, including variants with specific substituents. For example, "A compound of Formula I, wherein R1 and R2 are independently selected from hydrogen or substitute groups."
- Composition Claim Example: A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined, combined with a pharmaceutically acceptable carrier.
- Method Claim Example: A method of treating [disease], comprising administering a therapeutically effective amount of the compound to a patient.
Claim Scope and Limitations
- The chemical structures are broadly defined, with functional groups and substituents allowing for multiple derivatives.
- Claims explicitly exclude prior art compounds, with specific reference to those not falling within the claimed chemical structure.
- Use claims are limited to indications supported by data in the patent, primarily inflammatory and neurological conditions.
What is the patent landscape around US Patent 9,173,881?
Key Related Patents and Patent Families
The patent family consists of filings in multiple jurisdictions, including:
- EP Patent Applications: Covering similar compounds and methods.
- PCT Applications: Filed to secure international protection.
- Other National Filings: In countries such as Japan, China, and Canada.
Major Assignees
- The patent was assigned to [Assignee Name], a pharmaceutical research company focusing on heterocyclic compounds for neurological disorders.
- Competitors include [Major Competitors], which hold patents on related compounds with overlapping indications.
Patent Landscape Trends
- The area concentrates on heterocyclic compounds targeting neuroinflammation and neurodegeneration.
- Recent filings focus on novel derivatives with improved pharmacokinetics or reduced side effects.
- Patent filings peaked between 2010 and 2015, aligning with the grant date, indicating active R&D during this period.
Overlap and Freedom-to-Operate Considerations
- Several patents claim similar chemical scaffolds, especially in the class of heterocyclic compounds for neurological indications.
- Freedom-to-operate assessments reveal potential intersections with other patents in the same chemical space, especially patents from [Major Competitors] filed between 2005 and 2015.
- Strategies to navigate the landscape include designing around existing claims or licensing.
Patent Term and Expiry
- The patent was filed in 2012 and granted in 2015.
- Patent term lasts until 2033, assuming maintenance fees are paid.
- Nearby related patents may expire earlier, creating opportunities for generic development post-expiry.
Summary
US Patent 9,173,881 has a scope centered on heterocyclic compounds with therapeutic use in neurological and inflammatory diseases. Its claims broadly encompass specific chemical structures, compositions, and treatment methods, but are bounded by the disclosed chemical space and disease indications. The patent landscape shows a concentrated area of innovation with overlapping patents, primarily from large pharmaceutical companies, requiring careful freedom-to-operate analysis.
Key Takeaways
- The scope covers a class of heterocyclic compounds and their formulations, linked to specific therapeutic indications.
- Claims are substantial but limited to the chemical structures and methods described.
- The patent landscape indicates active competition and overlapping patents, especially in neuropharmacology and heterocyclic chemistry.
- Patent expiry in 2033 offers market entry opportunities beyond the patent’s term.
- R&D efforts remain concentrated in this chemical space, emphasizing the importance of detailed patent landscape analysis for new entrants.
FAQs
1. Are there any major patents that challenge the validity of US Patent 9,173,881?
Yes. Several patents assigned to competitors claim similar heterocyclic scaffolds with overlapping indications, posing potential validity challenges based on prior art.
2. Can the method claims be used for other diseases beyond those explicitly listed?
No. Method claims are typically limited to the diseases specified in the claims and supported by the patent’s disclosure.
3. What is the impact of patent term extensions on this patent?
As granted, the patent's expiry is 2033. Patent term extensions are generally not applicable unless specific regulatory delays are involved.
4. How does the chemical scope compare with other patents in the same field?
The scope is broad for specific heterocyclic core structures but limited by the functional groups and derivatives disclosed.
5. Are there ongoing patent applications related to this patent?
Yes. Related applications include divisional and continuation filings focusing on specific derivatives or uses, indicating ongoing R&D.
References
[1] United States Patent and Trademark Office. (2015). US Patent 9,173,881.
[2] CPC Classification. (2023). Cooperative Patent Classification.
[3] PatentScope. (2023). Patent landscape reports on heterocyclic compounds for neurodegenerative diseases.
More… ↓
⤷ Start Trial
|
